DNA X, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | $58.3M | $93.6M | $69.8M | $54.6M |
| Cost of revenue | — | $48.4M | $74.3M | $58.2M | $48.2M |
| Gross profit | — | $9.9M | $19.3M | $11.6M | $6.4M |
| Research and development | — | $14.2M | $1.8M | $8.0M | $17.7M |
| Operating expenses | $5.4M | $3.1M | $18.8M | $25.9M | $44.4M |
| Operating income | -$5.4M | -$3.1M | $513,000 | -$14.3M | -$38.0M |
| Interest expense | $945,000 | — | — | $97,000 | — |
| Pretax income | -$8.0M | -$2.9M | $284,000 | -$13.9M | -$38.5M |
| Income tax expense | -$1.1M | $226,000 | $374,000 | $184,000 | $167,000 |
| Net income | -$20.7M | -$33.6M | -$90,000 | -$14.1M | -$38.6M |
| Balance Sheet | |||||
| Cash and equivalents | $1.3M | $5.3M | $9.4M | $13.2M | $11.2M |
| Current assets | $28.9M | $32.2M | $43.8M | $43.6M | $35.7M |
| Total assets | $43.9M | $39.7M | $56.0M | $53.7M | $41.1M |
| Current liabilities | $48.0M | $43.7M | $32.1M | $32.1M | $21.0M |
| Total liabilities | $50.6M | $45.4M | $33.7M | $33.6M | $22.5M |
| Total debt | $5.7M | — | — | — | — |
| Stockholders' equity | -$8.0M | -$5.7M | $22.4M | $20.0M | $18.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$23.5M | -$8.5M | -$4.1M | -$12.4M | -$38.5M |
| Depreciation and amortization | $4.3M | $58,000 | $47,000 | $244,000 | $2.1M |
| Stock-based compensation | $1.5M | $1.5M | $1.5M | $1.6M | $1.1M |
| Capital expenditure | — | $214,000 | $36,000 | $8,000 | $46,000 |
| Free cash flow | — | -$8.7M | -$4.1M | -$12.4M | -$38.5M |
| Impairments | $2.1M | $6.5M | — | — | — |
Shares outstanding 1.5M
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.